<DOC>
	<DOCNO>NCT01654718</DOCNO>
	<brief_summary>This study compare single-dose oral bioequivalence Pantoprazole sodium 40 mg delay release tablet ( contain 45.1 mg Pantoprazole sodium sesquihydrate equivalent 40 mg Pantoprazole ) OHM Laboratories Inc. USA ( subsidiary Ranbaxy Pharmaceuticals Inc. USA ) PROTONIXÂ® 40 mg delay release tablet ( contain 45.1 mg Pantoprazole sodium sesquihydrate equivalent 40 mg Pantoprazole ) Wyeth Laboratories , USA healthy , adult , human , male subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study</brief_title>
	<detailed_description>The study open-label , balance , randomize , two-treatment , two-period , two-sequence , single-dose , crossover , bioequivalence feed condition A washout period 08 day enforce administration study drug period . At study check-in , subject report clinical site least 36 hour prior Day 1 dosing require stay 24 hour Day 1 dosing . Blood sample collection obtain within 90 minute prior dose ( 0 hour ) dose administration periodic interval 48.00 hour period . A total number blood draw study sixty six ( 66 ) total volume blood drawn exceed 324 mL . Following overnight fast least 10 hour , high-fat high-calorie breakfast serve study subject . Thirty minute start breakfast , single oral dose Pantoprazole delay release tablet 40 mg either test reference formulation administer period study , along 240 mL drink water ambient temperature low light condition supervision train study personnel . Both test reference product administer study subject , one period .</detailed_description>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Volunteers meet follow criterion include study Were age range 1845 year . Were neither overweight underweight height per Life Insurance Corporation India height/weight chart nonmedical case . Had voluntarily give write informed consent participate study . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . Had nonvegetarian dietary habit . There deviation regard History allergy hypersensitivity Pantoprazole and/or drug . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . Presence value acceptable limit haemoglobin , total white blood cell count , differential WBC count platelet count . Positive urinary screen test drug abuse ( opiates cannabinoids ) . Presence value acceptable limit serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , epithelial cell ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . Clinically abnormal ECG Chest Xray . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma . History psychiatric illness might impair ability provide write informed consent . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . Use enzyme modifying drug within 30 day prior Day 1 study . Participation clinical trial within 12 week precede Day 1 study . Subjects , completion study , would donate /or lose 350 ml blood past 3 month study participation . There deviation regard .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>